NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Shares

Posted: October 12, 2021 at 7:03 PM EDT|Update: 1 hour ago

EDEN PRAIRIE, Minnesota, 12 October 2021 / PRNewswire / – NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients with neurological conditions, announced today ‘hui that it launched a subscription project for a public offering of shares of its ordinary shares.

(PRNewsfoto / NeuroOne Medical Technologies Corporation)

All of the common shares to be sold under the proposed offer will be sold by the Company. In addition, the Company intends to grant the Underwriter a 30 day option to purchase up to an additional 15% of the Common Shares sold under the Offer. The offered offer is subject to market and other conditions, and there can be no assurance that or when the offer can be made, nor as to the size or actual conditions of the offer.

The Company intends to use the net proceeds of this proposed offering for working capital and other general corporate purposes.

Craig-Hallum Capital Group is acting as the sole managing underwriter for the proposed offering.

The proposed offer is being made pursuant to a pre-registration statement on Form S-3 (File No. 333-256830) which has been declared effective by the United States Securities and Exchange Commission (“SEC”) on June 14, 2021. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available on the SEC’s website at or by contacting Craig-Hallum Capital Group LLC, 222 South Ninth Street, Suite 350, Minneapolis, Minnesota 55402, Attn .: Equity Capital Markets, Phone: 612-334-6300 or Email [email protected]

This press release does not constitute and will not constitute an offer to sell or the solicitation of an offer to buy any securities, and there will be no sale of such securities in any State or other jurisdiction in which such offering, solicitation or sale would be illegal. prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offering, if any, will be made only by means of a prospectus, including a prospectus supplement, forming part of the actual registration statement.

About NeuroOne

NeuroOne Medical Technologies Corporation is a developmental company committed to providing minimally invasive and high definition solutions for EEG recording, brain stimulation and ablation solutions for patients with epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain from failed back surgery, and other related neurological conditions that can improve patient outcomes and reduce procedural costs. For more information visit

Forward-looking statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views on future events and is subject to known and unknown risks, uncertainties and other factors. that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by such forward-looking statements. In some instances, you may identify forward-looking statements by the words “may”, “may”, “will”, “may”, “should”, “should”, “expect”, “intend to” “,” plan “,” objective “,” anticipate “,” believe “,” estimate “,” predict “,” project “,” potential “,” target “,” seek “,” contemplate “,” continue “and “In progress”, or the negative of those terms, or any other comparable terminology intended to identify statements about the future. Forward-looking statements include statements relating to the proposed offering and the intended use of the product. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that such statements are based on a combination of facts and factors currently known to us and our expectations for the future, of which we cannot be. some. Our actual future results may differ materially from what we expect due to factors largely beyond our control, including risks and uncertainties associated with market and other conditions, the satisfaction of customary closing conditions associated with the proposed public offering, the impact of general economic, industry or political conditions in United States or internationally and those described under the heading “Risk Factors” in our documents filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company assumes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available at that time. ‘to come up.

View original content to download multimedia:

SOURCE NeuroOne Medical Technologies Corporation

The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.

Comments are closed.